LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION

Levi & Korsinsky, LLP has announced a significant development in a securities class action concerning Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). The ongoing lawsuit, which pertains to a class period from August 3, 2023, to December 26, 2025, identifies the company's CEO Emil D. Kakkis and CMO Eric Crombez as control person defendants. This classification arises from their senior roles which purportedly allowed them to influence the content of the company's SEC filings, press releases, and presentations.

The legal action is anchored in Section 20(a) of the Securities Exchange Act, which can hold individuals liable if they control entities that violate securities laws. The complaint alleges that Kakkis and Crombez held substantial control and access to critical information, potentially misleading investors regarding study progress and associated risks. It is asserted that both executives, by virtue of their positions, received advance copies of reports and releases and had the capability to correct any deceptive statements prior to public dissemination.

Furthermore, the lawsuit highlights obligations under the Sarbanes-Oxley Act, which mandates senior executives to certify the accuracy of the company's reports. The complaint contends that Kakkis and Crombez signed these certifications while allegedly aware that the public statements were misleading.

Investors interested in participating in the class action must file by April 6, 2026. Joseph E. Levi, the attorney from Levi & Korsinsky, emphasized the responsibility of corporate officers to ensure that their companies’ public communications are accurate, stating an ongoing examination of the defendants’ involvement in the alleged misconduct. This case underscores the critical nature of transparency and accountability in the pharmaceutical sector, particularly in times of uncertainty.

In light of the recent announcement involving Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), where CEO Emil D. Kakkis and CMO Eric Crombez have been named as control person defendants in a pending securities class action, investors should reassess their positions on this stock. Allegations against the executives center around potential misleading public statements and a failure to uphold the transparency demanded by regulations under the Sarbanes-Oxley Act.

The implications of this lawsuit could be significant for Ultragenyx. Section 20(a) of the Securities Exchange Act suggests that if found liable, both Kakkis and Crombez could bear responsibility for any misrepresentations made while they were in control of key communications. If the lawsuit leads to financial penalties or any kind of settlement that impacts company resources, the resulting financial strain could adversely affect RARE's stock performance and investor confidence.

From a market perspective, potential investors should exercise caution. The stock may face volatility as the legal proceedings unfold. Historical trends in securities litigation indicate that companies entangled in allegations of this nature often see sharp declines in stock prices during the litigation period and uncertainties regarding leadership.

Investors currently holding shares in Ultragenyx may want to evaluate their positions, considering potential risks of further declines. It may also be advisable to diversify into less troubled assets or sectors until clarity on the lawsuit and the company's future direction emerges.

Overall, due diligence is recommended, and stakeholders are encouraged to stay informed about the developments of this legal action and any public statements from the company that could provide insight into the resolution of these issues.